Roche exceeds own guidance and achieves sales growth of 1%

1 February 2024

Shares of Swiss pharma giant Roche (ROG: SIX) were down nearly 4% at 370.55 francs today, after it released financial results for full-year 2023.

Full-year 2023 sales grew 1% to 58.7 billion Swiss francs ($67.99 billion), the firm said, which was slightly below an average analyst estimate of close to 60 billion francs according to LSEG data. Excluding COVID-19 products, group sales increased by 8%.

Pharmaceutical Division sales of 58.72 billion francs were up 1% at constant exchange rates (CER) and down 7% in francs. Diagnostics Division revenues plunged 135 at CER and 20% in francs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK